Avid Bioservices Inc (CDMO)

[biopharm]

Dr. Rolf Brekken : Peregrine Pharmaceuticals KOL : ... Salk Institute (Grem Lemke) to Kolltan to Medimmune (AstraZeneca)...etc..etc...etc

October 15, 2015 @ 04:00 PM
Pharmacology and Cancer Cell Networks Program Seminar Series

Greg E. Lemke, PhD, Salk Institute for Biological Studies. Biology of the TAM Receptors.

Rolf A. Brekken, PhD, host. Pickens Biomedical Bldg. (ND) 7.218.
Event Information

Event Starts
October 15, 2015 @ 04:00 PM

So, the biology of TAM receptors with Peregrine Pharmaceuticals KOL Rolf Brekken hosting Grem Lemke in house at UTSWM and what does that mean? You simply don't just invite Greg Lemke in house to discuss the biology of TAM receptors... the house that has been built upon the research of Phosphatidylserine and its targeting... all by the late Dr. Philip Thorpe, without it being directly related to PS Targeting.

I know... another run on sentence, but some just see Greg Lemke... and I say dig deeper and for you to realize that Greg Lemke has been studying PS Targeting or PtdSer through their ties to Bristol Myers Squibb or their funding I should say and who knows how the hell the tie is going but in the end PS Targeting is still the talk of the town and Rolf Brekken is hosting.

I'll post some of the ties below and one may find it confusing but one must follow along, because now it seems we are getting down to the basics of biology and who will be the first to say that PS Targeting must be incorporated into cancer immunotherapy for that full, robust, most optimal immune response? Maybe Greg Lemke... ??

----------------------------------------------

Read the post chain, especially the one before this post AND after you read it SLOWLY, then read this specific post below SLOWLY and finally, let it all sink in that Greg Lemke is coming in house to UTSWM with Dr. Rolf Brekken as host! Something big is being set up here and I thought I was losing my mind trying to figure out who and which one but there are dozens of them it seems and BAMMM -- you should realize you have dozens of solid reasons to back PPHM, yet a handful of some try to force you to focus on the pps. Shhhhhh, don't be fooled because a paradigm shifting, basic biology understanding of the immune system is truly at stake so don't for one second be fooled in any diversions from seeing the puzzle pieces. Lots of eyes on this now and you just need to learn where to look.

Salk Institute Findings May Lead to New Broad-Spectrum Antivirals

August 19, 2013

The Salk scientists found that a substance called phosphatidylserine (PtdSer), which is found on the surface of enveloped viruses (viruses with an outer wrapping of a lipid membrane), binds to extracellular proteins and activates TAM receptors on immune cells. In dendritic cells, a type of immune cell that interacts with T and B cells to initiate the adaptive immune response, TAM receptor activation turns off a set of genes called interferons that play a key role in antiviral defense. -

http://globalbiodefense.com/2013/08/19/salk-institute-findings-may-lead-to-new-broad-spectrum-antivirals/

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111843901

---------------------------------------------

Kolltan

Management

Gerald McMahon, Ph.D.
President and Chief Executive Officer

Jane Pritchett Henderson
Senior Vice President, Chief Financial and Business Officer

Theresa M. LaVallee, Ph.D.
Senior Vice President, Translational Medicine & Product Development

Keith J. C. Darragh, CPA, CGMA
Vice President, Finance & Administration and Treasurer

Ronald A. Peck, M.D.
Chief Medical Officer and SVP, Clinical Development


Board of Directors

Arthur G. Altschul, Jr.
Co-Founder and Chairman of the Board

Joseph Schlessinger, Ph.D.
Co-Founder, Director and Chairman of Scientific Advisory Board

Axel Bolte
Vice Chairman of the Board

K. Peter Hirth, Ph.D.
Director

Frank Karbe
Director

Gerald McMahon, Ph.D.
President, Chief Executive Officer and Director

Thomas B. Neff
Director

Daniel R. Vlock, M.D.
Director


Scientific Advisory Board

Joseph Schlessinger, Ph.D.
Co-Founder, Director and Chairman of Scientific Advisory Board

George D. Demetri, M.D.
Founding Chairman of the Kolltan Clinical Advisory Board and Member of Scientific Advisory Board

Carl-Henrik Heldin, Ph.D.
Member of Scientific Advisory Board

Roy S. Herbst, M.D., Ph.D.
Member of Scientific Advisory Board

Greg Lemke, Ph.D.
Member of Scientific Advisory Board

Mark A. Lemmon, Ph.D.
Member of Scientific Advisory Board

Benjamin G. Neel, M.D., Ph.D.
Member of Scientific Advisory Board

http://www.kolltan.com/people/

Interesting, Kolltan buys out Salk / Lemke patents, as Greg is studying PS Targeting and now Greg Lemke brought inside the operation and now being brought into the house of UTSWM. ...to be continued... because we have not even touched on the others involved here like the tie to Hakan Mellstedt (another Peregrine KOL)

so the puzzle gets bigger but at least we have a tie from Hakan Mellstedt to Gerald McMahon CEO of Kolltan...and PAV lists of some have shown Standish Fleming as well

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111909971